Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
Recruiting · NCT06505369 · Registry updated 2024-07-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2024-07-17 | NCT06505369 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Janssen Pharmaceutica | 7 |
| North Estonia Medical Centre | 6 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Copenhagen University Hospital (Rigshospitalet) | Copenhagen | Denmark | 4 |
| North Estonia Medical Centre | Tallinn | Estonia | 2 |
| Odense University Hospital | Odense | Denmark | 97 |
| Oslo University Hospital, Oslo Myeloma Centre | Oslo | Norway | 1 |
| St. Olavs Hospital | Trondheim | Norway | 17 |
| Stavanger University Hospital | Stavanger | Norway | 6 |
| Vejle Hospital | Vejle | Denmark | 12 |